All News

Adam Kittai, MD, reviews AMPLIFY data supporting acalabrutinib-venetoclax (AV) for CLL, citing strong safety and survival outcomes for select patients.

Rrisankizumab is the first and only IL-23 inhibitor FDA-approved for children aged 6 and older under 40 kg with plaque psoriasis or psoriatic arthritis.

Veligrotug-vvze (Lumvoa; Viridian Therapeutics) is the first treatment for thyroid eye disease (TED) that has been approved by the FDA with labeling that includes data for both active and chronic TED.

Summary of Nonconsensus Discussions: Bridging the Gaps in Health Equity & Access in Multiple Myeloma | May 2, 2026, Tampa, Florida

Obesity coding gaps limit care; MCL rising in women; racial pain disparities in oncology; AML access expands; SDOH rivals genetics.

New research reveals complex treatment costs from MM strain patients and caregivers during active therapy, while pain goes undertreated at end of life.

A single-center study found low rates of MRA and SGLT2 inhibitor prescribing among low-income, largely uninsured patients with heart failure.

Lower rates of successful discharge were reported in home health care patients whose care was interrupted by flooding related to hurricanes.

Participants highlight critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure.

Coverage of our peer-reviewed research and news reporting in the health care and mainstream press.

A population-based study linked male sex, Hispanic ethnicity, and select birth and parental factors to increased EOCRC risk.

A multidisciplinary Philadelphia roundtable surfaced the structural barriers that keep people with AD from reaching effective therapy.

Caregivers of patients with CKD report social withdrawal, strained relationships, and stigma, according to a new qualitative evidence synthesis.

An MRI study found hypothalamic atrophy across most subregions in adults with narcolepsy type 1, with the tuberal-inferior region relatively spared.

Spending on health expenditures will make up 20.6% of gross domestic product, according to a federal report.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

Independent investigations found that venetoclax-based combination regimens achieved high response and strong MRD negativity in newly diagnosed leukemias.

Epcoritamab shows high rates of first-line response and MRD negativity in older patients with chemo-ineligible DLBCL, whether used alone or with R-mini-CHOP.

SEER and Medicare data project rising DLBCL and MCL cases through 2032, intensifying payer strain and demand for Brukinsa, Calquence, and CAR-T access.

ASCO real-world oncology data show racial disparities in pain management, with delayed meds and fewer strong opioids for Black and Asian patients.

Deloitte's midyear analysis shows internal confidence rising even as external uncertainty over policy, tariffs, and reimbursement persists for biopharma and medtech.

FDA approves palbociclib (Ibrance) for HR+, HER2+ metastatic breast cancer maintenance, based on phase 3 PATINA data showing a 24% reduction in progression risk.

Interviews with patients living with generalized myasthenia gravis (MG) in the US revealed areas of increased burden in these patients.

A Medicare claims analysis found zanubrutinib was associated with significantly longer treatment duration and overall survival vs acalabrutinib and ibrutinib.

The move follows the close of a 42-day quarantine for American cruise-ship passengers exposed to the rare Andes strain.

Asthma biologics were associated with sustained reductions in exacerbations after 2015 across demographic and clinical subgroups in a large cohort study.

A study found significant drops in mean platelet volume and rises in platelet count after 6 months of SGLT2 inhibitor therapy, independent of diuretic use.

Claims data show a 4- to 6-fold increase in ATTR-CM diagnoses, with a growing comorbidity burden before diagnosis.